Table 5. TCR Vβ amplification ratios in Gag293-specific CD4+ T cell lines.
| Vβ specificity | HIV controllers | Treated patients | ||||||
| # 1 | # 2 | # 3 | # 4 | # 1 | # 2 | # 3 | # 4 | |
| 1 | - | 5 | 5 | - | 7 | - | 6 | 6 |
| 2 | - | - | - | - | - | - | - | - |
| 3 | - | - | - | - | - | - | - | - |
| 4 | - | - | - | 26 | - | - | - | - |
| 5.1 | - | - | 5 | 8 | - | - | - | 18 |
| 5.2 | 7 | 15 | - | - | - | - | - | - |
| 5.3 | 13 | 7 | - | - | - | 26 | - | - |
| 7.1 | - | 7 | - | - | 21 | - | 15 | |
| 7.2 | - | - | - | - | - | - | - | - |
| 8 | - | - | - | - | - | - | - | - |
| 9 | 16 | 7 | - | - | - | 6 | - | 14 |
| 11 | - | - | - | - | - | - | - | - |
| 12 | - | - | 39 | - | - | - | 7 | - |
| 13.1 | - | - | - | - | 25 | - | - | - |
| 13.2 | 5 | 4 | - | - | - | - | 5 | 25 |
| 13.6 | - | 9 | 4 | - | 20 | - | - | - |
| 14 | - | - | - | - | - | - | - | - |
| 16 | - | - | 40 | - | - | - | - | - |
| 17 | - | - | - | - | - | - | - | - |
| 18 | - | - | - | - | - | - | - | - |
| 20 | - | - | 5 | - | - | - | - | - |
| 21.3 | - | - | - | - | - | - | - | - |
| 22 | - | - | 5 | - | - | - | - | - |
| 23 | - | 4 | - | 8 | - | 20 | - | - |
| Total number of Vβ amplifications | 4 | 7 | 8 | 3 | 3 | 4 | 3 | 5 |
The ratio of tetramer-positive (Tet+) to tetramer-negative (Tet−) CD4+ T cells is given for each of the 24 Vβ specificities tested.
Only ratio ≥4 in populations of Tet+ cells ≥2% are reported.